Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of hepatocellular carcinoma.Hepatology. 2021; 73: 4-13
- Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2016; 14: 124-131.e1
- Surveillance for hepatocellular carcinoma: current best practice and future direction.Gastroenterology. 2019; 157: 54-64
- Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology. 2018; 154: 1706-1718.e1
- Reply to: ‘Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan’.J Hepatol. 2022; https://doi.org/10.1016/j.jhep.2022.04.031
- A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.Med (N Y). 2021; 2: 836-850.e10
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology. 2014; 59: 2188-2195
- Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology. 2018; 155: 1828-1837.e2
- Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis.Hepatology. 2021; 73: 713-725
- Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms.Am J Gastroenterol. 2020; 115: 1642-1649
- Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther. 2017; 45: 169-177
- Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.Hepatology. 2018; 67: 401-421
- MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma.JAMA Oncol. 2017; 3: 456-463
Marrero J.A., Parikh N.D., Roberts L.R., et al., GALAD score improves early detection of HCC prior to the diagnosis of HCC: a phase 3 biomarker validation study. American Association for the Study of the Liver. The Liver Meeting 2021.
- DCP and AFP-L3 are complementary to AFP in predicting high-risk explant features: results of a prospective study.Clin Gastroenterol Hepatol. 2022; 20: 701-703.e2
- Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.Liver Transpl. 2015; 21: 599-606
- Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma.J Hepatol. 2012; 56: 1371-1383
- Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation.Hepatology. 2019; 69: 1180-1192
- Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review.Clin Gastroenterol Hepatol. 2020; 18: 2879-2902.e9
- Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-β pathway.Gastroenterology. 2018; 154: 195-210
- Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med. 2008; 359: 1995-2004
- BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol. 2022; 76: 681-693
- Liver transplantation for hepatocellular carcinoma: foucault pendulum versus evidence-based decision.Liver Transpl. 2003; 9: 700-702
- Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.Hepatology. 2008; 48: 819-827
- Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis of the all-comers protocol.Hepatology. 2019; 70: 1185-1196
- National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time.Hepatology. 2020; 71: 943-954
- Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.Gastroenterology. 2018; 154: 128-139
- Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium.Gastroenterology. 2021; 161: 1502-1512
- Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.Lancet Oncol. 2020; 21: 947-956
- Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?.Lancet Oncol. 2020; 21: 867-869
- Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study.Transpl Int. 2020; 33: 567-575
- Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: a pilot study.Liver Transplant. 2021; 27: 1758-1766
- Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?.Am J Transplant. 2020; 20: 879-883
- Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review.Front Immunol. 2021; 12: 653437
- PD-1 inhibitor as bridge therapy to liver transplantation?.Am J Transplant. 2021; 21: 1979-1980
- An Eastern Hepatobiliary Surgery Hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study.Hepatology. 2019; 69: 2076-2090
- The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.J Surg Oncol. 2009; 99: 343-350
- Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.Eur J Surg Oncol. 2006; 32: 773-779
- Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.HPB (Oxford). 2019; 21: 1497-1504
- Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma.Cancer Immunol Res. 2019; 7: 1390-1395
- Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.J Clin Oncol. 2020; 38: 4599
- Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.Hepatology. 2021; 74: 483-490
- Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: an interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.J Clin Oncol. 2021; 39: 4008
- Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China.JAMA Surg. 2019; 154: 209-217
- Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: a PRISMA-compliant systematic review and meta-analysis.Medicine (Baltimore). 2020; 99: e22703
- Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis.HPB (Oxford). 2021; 23: 512-519
- Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?.Hepatology. 2008; 47: 82-89
- Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.Hepatology. 2009; 49: 453-459
- Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.Ann Surg. 2021; 273: 656-666
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2021; 18: 293-313
- Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma.Hepatology. 2015; 61: 1579-1590
- Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications.Eur Radiol. 2019; 29: 654-662
- Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.J Clin Oncol. 2013; 31: 426-432
- Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial.J Hepatol. 2014; 61: 1304-1311
- Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma.Cancer Lett. 2021; 496: 169-178
- Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma.Acta Biomater. 2021; 129: 245-257
- Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study.Hepatology. 2021; 74: 2342-2352
- Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.Lancet Gastroenterol Hepatol. 2021; 6: 17-29
- (90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial.Radiology. 2022; 303: 699-710
- Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review.Radiother Oncol. 2020; 145: 63-70
- Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial.JAMA Oncol. 2018; 4: 661-669
- Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging.Transplantation. 2020; 104: 2334-2345https://doi.org/10.1097/tp.0000000000003162
- TACTICS: final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).J Clin Oncol. 2021; 39: 270
- Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial.J Clin Oncol. 2022; 40: 380
- Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.J Clin Oncol. 2020; 38: 2960-2970
- Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: a real world study.J Clin Oncol. 2021; 39: e16138
D’Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. n/a(n/a)doi:https://doi.org/10.1002/hep.32468
Article info
Publication history
Published online: October 18, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
